Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update
Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th ...
MRK's sNDA for Welireg in Rare Tumors Gets FDA's Priority Tag
The FDA accepts and grants priority review to Merck's sNDA for Welireg to treat advanced pheochromocytoma and paraganglioma.
IDA Ireland8h
Ireland’s pillar of trust: the role of the regulator - HPRA
The HPRA is the national regulator across many different health products: medicines, particularly pharmaceuticals and ...
GSK says asthma and nasal polyps therapy under EU review
GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...
GSK's depemokimab gets EMA nod for asthma and nasal polyps
GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.29 billion and currently ...
x4 pharmaceuticals CEO sells shares worth $34,718
Paula Ragan, the President and CEO of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), recently sold 76,473 shares of the company's common stock. The shares were sold at a weighted average price of $0.454 per ...